{
    "nctId": "NCT02882113",
    "officialTitle": "Influence of CYP3A5 Polymorphism on Liver Function Abnormality and the Trough Level Change After Conversion From Tacrolimus (Bid) to Advagraf\u00ae (qd) in Stable Liver Transplant Recipients",
    "inclusionCriteria": "* 19 years old and above.\n* Patients who previously have received a liver transplant over the last six months and within last three years.\n* Patients who are on Tacrolimus immunosuppressive therapy twice a day for at least two weeks.\n* During Tacrolimus immunosuppressive therapy twice a day for at least two weeks, patients who have following conditions.\n\n  * Patients who have normal liver function and renal function.\n  * Patients who have been monitored without complication such as acute rejection.\n* Patients willing to sign his/her consent.\n* Must have minimum age of 19 Years",
    "exclusionCriteria": "* Patients who have Tacrolimus trough level resulted as 2 ng/mg at the baseline.\n* Patients who are on steroid therapy due to positive result of acute rejection test before the baseline.\n* Patients who have received a transplant besides liver.\n* Patients who are allergic to IP or macrolide compounds.\n* Patients who are on cyclosporine, bosentan, or potassium sparing diuretic.\n* Patients with genetic diseases such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.\n* Pregnant or lactating women.\n* Patients not willing to adhere to study procedures/treatments."
}